Group 1 - Pharma, biotech, and healthcare stocks in Asia are experiencing declines following President Trump's announcement of a 100% tariff on branded or patented drugs entering the United States, effective October 1st [1] - An exemption from the tariff will be available for companies that are establishing drug manufacturing plants in the U.S., including those already in the process of building [2] - European companies such as AstraZeneca, RO, and Novartis are planning significant investments in the U.S. over the next four to five years to mitigate potential impacts from tariffs [3] Group 2 - Analysts at JP Morgan suggest that large-cap biopharma companies are likely to avoid the new tariffs due to their increased presence in the U.S. and inventory builds that will limit exposure until mid-next year [4] - A company with 13 manufacturing sites in the U.S. reports having free capacity and is well-prepared for potential tariff impacts, indicating a favorable trade balance with more exports than imports in certain active ingredients [5] - The clarity regarding future operations allows companies to effectively set up their supply chains and operations in response to the evolving trade landscape [6]